Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] ALTEOGEN (196170) – Change of Market Division / 2025-04-30

Posted on April 30, 2025August 5, 2026 By K-STOCK Editor No Comments on [Disclosure] ALTEOGEN (196170) – Change of Market Division / 2025-04-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

ALTEOGEN announced that its KOSDAQ market division assignment has been changed from ‘Technology Growth Business Division’ to ‘Premier Business Division’ upon satisfying the regular qualification criteria for Premier status. The change takes effect on May 02, 2025.

📊 [Key Disclosure Details & Major Figures Summary]

  • Company Name: ALTEOGEN Inc. (Ticker: A196170)
  • Change Details:
    • Previous Division: Technology Growth Business Division
    • New Division: Premier Business Division
  • Reason for Change: Meeting regular qualification criteria for Premier status
  • Effective Date: May 02, 2025

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Market Division Transfer and Official System Reflection

This disclosure formally announces the reclassification of ALTEOGEN’s KOSDAQ market division based on KRX’s periodic review. Confirming that the division change to Premier Business Division is properly reflected in the exchange system on the effective date (May 02, 2025) is essential because it allows investors to verify the company’s updated market classification. Detailed updates can be cross-checked on the KRX KIND system and in subsequent periodic filings.

📢 Disclaimer & Source Notice

Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Change of Market Segment / 2025-04-30
Next Post: [Disclosure] Hanwha Aerospace (012450) Amends Schedule and Adjustment Formulas for Stock Futures/Options Market Measures Following Revised Capital Increase Timeline

Related Posts

[Disclosure] SK Hynix (000660) – Market Action & Information Notice (Ex-Dividend Reference Price) / 2024-03-27 Disclosures
[Disclosure] ALTEOGEN (196170) – Holding of Investor Relations (IR) Session / 2024-11-08 Disclosures
[Disclosure] Hanwha Aerospace (012450) Signs KRW 941.4B Defense Export Execution Agreement with KOTRA for Finland Project Disclosures
[Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2025-02-17 Semiconductors
[Disclosure] HPSP (403870) – Corporate Value-up Plan / 2026-04-30 Semiconductors
[Disclosure] LEENO Industrial (058470) – Decision on Cash/In-Kind Dividend / 2024-02-08 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme